• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Quantitative molecular monitoring of HIV-1 RNA during antiretroviral therapy.

作者信息

Lafeuillade A, Poggi C, Pellegrino P, Profizi N

机构信息

Dept. of Infectious Diseases, Hôpital Chalucet, Toulon, France.

出版信息

Infection. 1996 Nov-Dec;24(6):412-8. doi: 10.1007/BF01713040.

DOI:10.1007/BF01713040
PMID:9007587
Abstract

Plasma HIV-1 RNA testing was used to monitor 43 HIV-1 infected patients newly placed on antiretroviral therapy or whose therapy had been recently changed. A polymerase chain reaction kit was used to measure HIV-1 RNA in clinical samples or frozen plasma. The cutoff of this test was 200 RNA copies/ml. The first group (11 patients) was stable on long-term zidovudine monotherapy when switched to stavudine. The HIV-1 RNA of three patients who had a regular decline in CD4+ T cell count did not change despite this switch, with a mean follow-up of 630 days. The HIV-1 RNA copy numbers of eight patients whose CD4+ T cell counts were stable declined an average of 0.53 log10 between days 90 and 650. The second group (14 patients) was on long-term zidovudine monotherapy and had declining CD4+ T cell counts over the past 6 months. Lamivudine was added to this regimen on day 0. HIV-1 RNA copy number decreased rapidly within 30 d, reaching -0.86 log10 on day 90, and this effect was maintained thereafter, with a mean follow-up of 161 days. There was a concomitant mean gain of +33 CD4+ T cells on day 90. The third group (nine patients) had never received anti-retroviral therapy and was given zidovudine+didanosine. HIV-1 RNA copy number decreased in all cases but one, reaching -1.31 log10 on day 150. This decrease was transient in three cases. The last group (nine patients) had also not had previous anti-retroviral therapy and was given zidovudine + didanosine + lamivudine in combination. HIV-1 RNA copy numbers declined rapidly in all cases, to below the cutoff in eight cases within a mean period of 50.5 days. The CD4+ cell counts increased by 164 cells/microliter on day 14 and by 201 cells/microliter on day 180. The response to therapy of the total population of 43 patients varied according to cases. The relative changes in p24 antigen compared to HIV-1 RNA also differed between patients. Measurement of HIV-1 viremia appears to be a valuable tool in current practice for individualizing therapy.

摘要

相似文献

1
Quantitative molecular monitoring of HIV-1 RNA during antiretroviral therapy.
Infection. 1996 Nov-Dec;24(6):412-8. doi: 10.1007/BF01713040.
2
A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.一项随机研究,比较三联与双联抗逆转录病毒疗法或不治疗对极早期HIV-1感染患者的效果:西班牙Earth-1研究
AIDS. 1999 Dec 3;13(17):2377-88. doi: 10.1097/00002030-199912030-00009.
3
Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.抗逆转录病毒联合疗法(齐多夫定/去羟肌苷或齐多夫定/拉米夫定)对感染人类免疫缺陷病毒的儿童和青少年血浆中人类免疫缺陷病毒核糖核酸定量的影响。
J Pediatr. 1997 Feb;130(2):293-9. doi: 10.1016/s0022-3476(97)70358-5.
4
Quantification of HIV-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy.淋巴和血细胞中HIV-1病毒载量的定量分析:四联疗法期间的评估
AIDS. 1997 Jun;11(7):895-901. doi: 10.1097/00002030-199707000-00009.
5
Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed.在接受包括蛋白酶抑制剂在内的多种抗逆转录病毒治疗均失败的患者中,将地拉韦啶添加到联合治疗方案中的临床经验。
AIDS. 1998 Jul 30;12(11):1333-40. doi: 10.1097/00002030-199811000-00015.
6
Pilot study of zidovudine-lamivudine combination therapy in vertically HIV-infected antiretroviral-naive children.齐多夫定-拉米夫定联合疗法用于未接受过抗逆转录病毒治疗的垂直感染艾滋病毒儿童的初步研究。
AIDS. 1998 Mar 26;12(5):489-94. doi: 10.1097/00002030-199805000-00010.
7
Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.ALBI试验结果:对初治抗逆转录病毒治疗患者中司他夫定/去羟肌苷、齐多夫定/拉米夫定及交替治疗的随机对照比较
Antivir Ther. 1999;4 Suppl 3:71-4.
8
Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.拉米夫定联合齐多夫定、司他夫定或去羟肌苷治疗HIV-1感染患者。一项随机、双盲、安慰剂对照试验。美国国立过敏与传染病研究所艾滋病临床试验组方案306研究人员。
AIDS. 1999 Apr 16;13(6):685-94. doi: 10.1097/00002030-199904160-00009.
9
Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.拉米夫定与齐多夫定联合疗法在曾接受齐多夫定治疗患者中的安全性和疗效。与齐多夫定单药疗法的随机对照比较。欧洲拉米夫定艾滋病工作小组
JAMA. 1996 Jul 10;276(2):111-7.
10
Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.拉米夫定-齐多夫定联合疗法在初治抗逆转录病毒治疗患者中的安全性和疗效。与齐多夫定单药疗法的随机对照比较。欧洲拉米夫定HIV工作组
JAMA. 1996 Jul 10;276(2):118-25.

本文引用的文献

1
Triple combinations: present and future.三联组合:现状与未来。
J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S77-82.
2
Zidovudine and lamivudine: results of phase III studies.齐多夫定与拉米夫定:III期研究结果
J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S57.
3
Individualization of therapy using viral markers.
J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S41-6.
4
Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.血浆中人类免疫缺陷病毒1型(HIV-1)RNA及CD4+淋巴细胞计数的变化与发展为艾滋病的风险。退伍军人事务部艾滋病合作研究小组
N Engl J Med. 1996 Feb 15;334(7):426-31. doi: 10.1056/NEJM199602153340703.
5
Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection.齐多夫定与去羟肌苷联合治疗与齐多夫定单药治疗在HIV-1感染中的比较。
Ann Intern Med. 1993 Oct 15;119(8):786-93. doi: 10.7326/0003-4819-119-8-199310150-00003.
6
Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection.用于定量检测血浆中1型人类免疫缺陷病毒RNA的快速简易聚合酶链反应检测法:在急性逆转录病毒感染中的应用
J Clin Microbiol. 1994 Feb;32(2):292-300. doi: 10.1128/jcm.32.2.292-300.1994.
7
Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories.血清p24抗原水平作为齐多夫定治疗1型人类免疫缺陷病毒感染者临床试验的中间终点。艾滋病临床试验组病毒学实验室。
J Infect Dis. 1994 Apr;169(4):713-21. doi: 10.1093/infdis/169.4.713.
8
High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.通过竞争性聚合酶链反应确定,在感染的所有阶段血浆中均存在高水平的HIV-1。
Science. 1993 Mar 19;259(5102):1749-54. doi: 10.1126/science.8096089.
9
Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy.
J Infect Dis. 1994 Nov;170(5):1157-64. doi: 10.1093/infdis/170.5.1157.
10
Quantification of human immunodeficiency virus in plasma by RNA PCR, viral culture, and p24 antigen detection.通过RNA聚合酶链反应、病毒培养和p24抗原检测对血浆中的人类免疫缺陷病毒进行定量分析。
J Clin Microbiol. 1994 Jul;32(7):1669-73. doi: 10.1128/jcm.32.7.1669-1673.1994.